ClinicalTrials.gg
RecruitingNCT03884673Updated Sep 14, 2022

Dolutegravir Plus Lamivudine Simplified Therapy

An observational study in HIV/AIDS, sponsored by Guangzhou 8th People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-14.

Sponsored by Guangzhou 8th People's Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2019; still recruiting 7 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital — 10 open to participants now, 10 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · Guangzhou 8th People's Hospital.

Started
2019
with 1 other
Observational
8 of 11
8 open now
Registered
3rd of 11
by date

Among the 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital, this one is one of 2 that started in 2019, is one of 8 observational ones, and was the 3rd registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

10 of the 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acquired Immunodeficiency Syndrome by Guangzhou 8th People's Hospital, or all of them as a file.
02

Study summary

Dolutegravir (DTG) is one type of integrase inhibitor, lamivudine (3TC) is one type of reverse transcriptase inhibitor, both of which are HIV medicine prevents HIV from self-multiplying, reduces the viral load. The data of the existing randomized controlled clinical studies show that the simplified two-drug DTG-based regimen is similar to the three-drug regimen in terms of efficacy, but there are no relevant data and reports on the efficacy and safety of DTG+3TC in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of the DTG + 3TC regimen for HIV-infected patients in real clinical environment, to guide clinical application, and to provide a theoretical basis for the selection of simplified schemes for the formulation of guidelines.

This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG, Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and well-tolerated treatment for HIV.

Read the detailed description

This study is an open-label, multicentered, single-arm and phase IV clinical trial. 300 HIV-infected patients who received simplified treatment regimen (50mg DTG+ 400mg 3TC, oral, qd) were selected to observe the treatment efficacy. At week 24, 36, 48 and 96, the rate of viral suppression and CD4 cell count were calculated against baseline. In addition, the safety and drug compliance were also monitored.

03

Conditions studied

  • HIV/AIDS

Keywords

  • DTG + 3TC Simplified Therapy
  • Simplified Therapy Regimen
  • Real World Study
  • HIV-1-infected patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who are prescribed to take the simplified therapy regimen (DTG+ 3TC) because they are unable to tolerate the side-effect of or are not fit for the first-line free regimen in China, for example renal failure or osteoporosis, according to clinical judgment, no matter of the HIV-RNA viral loads and CD4 cell counts.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age (> 18 years), male and female;
  2. -1 infected;
  3. Using a standard three-drug-based regimen for at least 24 weeks. Based on clinical decision making* decide if patients can be treated with the DTG+3TC simplified scheme for a variety of reasons, such as (but not limited to): patients cannot tolerate the conventional three-drug treatment scheme, renal insufficiency, osteoporosis, bone marrow suppression and for other reasons patients cannot use the conventional three-drug treatment scheme;
  4. Initial HIV-1 RNA viral load and were unlimited.
  5. CD4 can be monitored at least three times in the first year (including baseline, 24 weeks of treatment and 48 weeks of treatment). After the first year, CD4 can be detected at least once every six months.
  6. State for Free Treatment has been signed;
  7. Good compliance and signing Informed Consent

(* Reference criteria: Refer to APSIRE study, rate (> 50 mL/min), no DTG/3TC allergy history, negative, no chronic liver disease, no severe liver damage, no pregnancy during the study)

Exclusion criteria

Exclusion Criteria:

  1. Has participated in other clinical trials of vaccine or other drug trials in the past three months;
  2. Researchers decide if patients could/not complete the scheduled follow-up (factors to consider such as weak, poor compliance, etc.).
  3. Has a clear history of DTG or 3TC allergy;
  4. and/or HBV-DNA positive;
  5. Pregnancy during the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • DTG+3TC

    These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).

    Drug: DTG+ 3TC

Interventions

06

What researchers measure

Primary outcomes

  1. Virus suppression rate

    ratio of HIV RNA \< 50 copies/mL at 48 and 96 weeks of treatment

    Time frame: 96 weeks

  2. Adverse events

    Rate of adverse events reported during the observational period

    Time frame: 96 weeks

Secondary outcomes

  1. The immunological ability (CD4+)

    CD4 cell count (baseline to 48 weeks and 96 weeks)

    Time frame: 96 weeks

  2. Drug compliance

    To explicit the number of people who have completed the treatment

    Time frame: 96 weeks

  3. The immunological ability (CD8+)

    CD4 +/ CD8 + ratio (baseline to 48 weeks and 96 weeks)

    Time frame: 96 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum In: Lancet. 2019 Jan 12;393(10167):132. doi: 10.1016/S0140-6736(18)33041-1. PubMed 30420123 ↗
  • Cahn P, Rolon MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017 May 9;20(1):21678. doi: 10.7448/IAS.20.01.21678. PubMed 28537061 ↗
  • Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083. PubMed 29253097 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2025, 83 months after the start.

Of 165 non-industry observational studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 83 months is above that.

Counting every sponsor, half of 177 studies reached it within 44 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2019
First posted
Mar 21, 2019
StartActual
Jan 1, 2019
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2030
Last update
Sep 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03884673
Lead sponsor
Guangzhou 8th People's Hospital
Collaborators
Shenzhen Third People's Hospital, Dongguan People's Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, The Third People's Hospital of Guilin, Guangxi Longtan hospital, The Fourth People's Hospital of Nanning, The Third People's Hospital of Kunming, Yunnan AIDS Care Center, Meng Chao Hepatobiliary Hospital of Fujian Medical University, First Affiliated Hospital of Guangxi Medical University
Responsible party
Linghua LI (Vice Chief physician, Guangzhou 8th People's Hospital) — Principal investigator
First posted
Mar 21, 2019
Start date
Jan 1, 2019
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 14, 2022

Study contacts

Linghua Li, PhD
Contact
llheliza@126.com
020-83710825
Weiping Cai, Bachelor
Contact
gz8hcwp@126.com
020-83710825
Weiping Cai, Bachelor
principal investigator · Guangzhou 8th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion